These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 32461123

  • 21. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
    Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, Onishi A, Jinno S, Hara R, Son Y, Amuro H, Takeuchi T, Yoshikawa A, Katayama M, Yamamoto K, Okita Y, Hirao M, Etani Y, Kumanogoh A, Okada S, Nakata K.
    Sci Rep; 2022 Jan 07; 12(1):134. PubMed ID: 34997059
    [Abstract] [Full Text] [Related]

  • 22. Herpes simplex infection in a patient with rheumatoid arthritis treated with baricitinib: a case report.
    Valor-Méndez L, Voskens C, Rech J, Kleyer A, Schett G.
    Rheumatology (Oxford); 2021 Apr 06; 60(4):e122-e123. PubMed ID: 33141876
    [No Abstract] [Full Text] [Related]

  • 23. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
    Lee YH, Song GG.
    Z Rheumatol; 2020 Oct 06; 79(8):785-796. PubMed ID: 32055928
    [Abstract] [Full Text] [Related]

  • 24. Cryptococcal pneumonia in a patient with rheumatoid arthritis treated with baricitinib.
    Li J, Yu Y, Xie J, Jiang Y, Lu L.
    Rheumatology (Oxford); 2021 Dec 24; 61(1):e6-e7. PubMed ID: 34424311
    [No Abstract] [Full Text] [Related]

  • 25. Resolution of exacerbated rheumatoid arthritis-associated interstitial lung disease under baricitinib treatment.
    Komai T, Sawada T, Tsuchiya H, Harada H, Shoda H, Fujio K.
    Scand J Rheumatol; 2024 Mar 24; 53(2):146-148. PubMed ID: 38031721
    [No Abstract] [Full Text] [Related]

  • 26. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
    Winthrop KL, Harigai M, Genovese MC, Lindsey S, Takeuchi T, Fleischmann R, Bradley JD, Byers NL, Hyslop DL, Issa M, Nishikawa A, Rooney TP, Witt S, Dickson CL, Smolen JS, Dougados M.
    Ann Rheum Dis; 2020 Oct 24; 79(10):1290-1297. PubMed ID: 32788396
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Wang F, Sun L, Wang S, Davis JM, Matteson EL, Murad MH, Luo F, Vassallo R.
    Mayo Clin Proc; 2020 Jul 24; 95(7):1404-1419. PubMed ID: 32499126
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.
    Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, Macias W.
    J Rheumatol; 2016 Mar 24; 43(3):504-11. PubMed ID: 26834213
    [Abstract] [Full Text] [Related]

  • 29. Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry.
    Takahashi N, Asai S, Kobayakawa T, Kaneko A, Watanabe T, Kato T, Nishiume T, Ishikawa H, Yoshioka Y, Kanayama Y, Watanabe T, Hirano Y, Hanabayashi M, Yabe Y, Yokota Y, Suzuki M, Sobue Y, Terabe K, Ishiguro N, Kojima T.
    Sci Rep; 2020 Dec 14; 10(1):21907. PubMed ID: 33318522
    [Abstract] [Full Text] [Related]

  • 30. Baricitinib and tofacitinib in patients with rheumatoid arthritis: results of regular clinical practice.
    González-Freire L, Giménez-Candela RM, Castro-Luaces S, Veiga-Villaverde AB, Crespo-Diz C.
    Farm Hosp; 2021 Jun 01; 45(4):165-169. PubMed ID: 34218760
    [Abstract] [Full Text] [Related]

  • 31. Baricitinib in Patients with Refractory Rheumatoid Arthritis.
    Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, Macias WL, de Bono S, Schlichting DE, Smolen JS.
    N Engl J Med; 2016 Mar 31; 374(13):1243-52. PubMed ID: 27028914
    [Abstract] [Full Text] [Related]

  • 32. Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome.
    Nousari Y, Wu BC, Valenzuela G.
    Clin Exp Dermatol; 2021 Oct 31; 46(7):1330-1332. PubMed ID: 33914946
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.
    Tanaka Y, Atsumi T, Amano K, Harigai M, Ishii T, Kawaguchi O, Rooney TP, Akashi N, Takeuchi T.
    Mod Rheumatol; 2018 Jul 31; 28(4):583-591. PubMed ID: 29134891
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase.
    Vallejo-Yagüe E, Weiler S, Micheroli R, Burden AM.
    Drug Saf; 2020 Sep 31; 43(9):881-891. PubMed ID: 32533433
    [Abstract] [Full Text] [Related]

  • 40. A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis.
    Schlueter M, Rouse P, Pitcher A, Graham-Clarke PL, Nicolay C, Fakhouri W.
    Expert Rev Pharmacoecon Outcomes Res; 2020 Apr 31; 20(2):221-228. PubMed ID: 32212867
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.